logo
RFK Jr.‘s mass firing of the government's vaccine experts, explained

RFK Jr.‘s mass firing of the government's vaccine experts, explained

Voxa day ago

covers health for Vox, guiding readers through the emerging opportunities and challenges in improving our health. He has reported on health policy for more than 10 years, writing for Governing magazine, Talking Points Memo, and STAT before joining Vox in 2017.
For the past 60 years, a committee of independent experts has advised the federal government on vaccine policy, providing guidance on which shots people should get and when. Government public health officials have almost always followed the panel's recommendations, all but making it the final word on public health policy in the US for most of its existence. And over those decades, the United States has made tremendous health gains over that time through mass vaccination campaigns.
But on Monday, Health Secretary Robert F. Kennedy Jr. fired every sitting member of the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP), a move that stunned doctors and scientists across the country. And it means that the CDC's days as the clear and unchallenged authority on US vaccine policy appear numbered.
'Up until today, ACIP recommendations were the gold standard for what insurers should pay for, what providers should recommend, and what the public should look to,' Noel Brewer, a health behavior professor at the University of North Carolina, who was a member of the panel until this week, told the Associated Press. 'It's unclear what the future holds.'
Today, Explained
Understand the world with a daily explainer plus the most compelling stories of the day, compiled by news editor Sean Collins. Email (required)
Sign Up
By submitting your email, you agree to our Terms and Privacy Notice . This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
New committee members will be announced at some point, but as of Tuesday morning, even top US senators did not know who the replacements would be. The panel is supposed to hold one of its periodic public meetings in late June to discuss the Covid-19 vaccine, as well as shots for RSV and HPV, among others.
This is a watershed moment in US public health, one that seems sure to sow confusion among patients and health care providers. The deepening divide between Kennedy's Make American Healthy Again (MAHA) movement and mainstream medicine could make it harder for people who want vaccines to get them, while encouraging more doubt about the value and safety of shots among the general public. Here's what you need to know.
Why is Kennedy doing this?
The vaccine advisory committee was first convened by the surgeon general in 1964, but it is not enshrined in federal law. That means that Kennedy — as the top official at the US Department of Health and Human Services, which contains the CDC — can change its membership or dissolve the panel entirely if he so desires.
Kennedy framed his decision to clear out the members as necessary to restore public trust in the government's vaccine recommendations. In a Wall Street Journal op-ed, Kennedy asserted the committee 'has been plagued with persistent conflicts of interest and has become little more than a rubber stamp for any vaccine.'
As health secretary, he has made overhauling vaccine policy a centerpiece of his agenda, both through his rhetoric and policy. Over the past few months, while the worst measles outbreak in 30 years has spread through the US, Kennedy has equivocated in public comments on the value of the measles vaccine, which doctors say is far and away the best tool to combat the disease. He directed an anti-vaccine researcher to scour federal data for evidence of a vaccine-autism link. His department's recent MAHA report on childhood chronic disease named vaccines as one example of how the US overmedicalizes its children and exposes them to artificial agents that could do harm to their body.
Then in late May, Kennedy oversaw a revision of the federal government's Covid-19 vaccine guidance, limiting the shots to elderly people and those who are immunocompromised. He ended the recommendation that pregnant women and kids get a Covid vaccine shot, even though studies have shown they help confer immunity to infants, who are at a higher risk from the virus and cannot be vaccinated until they are 6 months old. The move plainly circumvented ACIP's accepted role in setting vaccine policy, presaging this week's mass firing.
Whatever his intentions, Kennedy's gutting of the federal vaccine committee seems likely to sow even more distrust — and certainly more confusion. People are reasonably left to wonder whether they can trust forthcoming CDC guidance on vaccines, and just what vaccines they'll be able to get.
How will I know which vaccines to get?
In the past, ACIP would typically meet a few times a year to discuss any additions or changes to the country's vaccine schedule. Their recommendations have usually been adopted without alterations by the CDC director, and then became the standard for state and local health departments across the country. Importantly, most health plans are required to cover any shots that the committee recommends.
Now there is far more uncertainty. Will doctors follow the CDC guidance, even if it changes under a new advisory panel staffed by Kennedy loyalists, or will they stick with the earlier vaccine schedule? Will health insurance plans cover the cost of a vaccine that professional medical organizations support but the CDC does not? Once-unthinkable questions could soon be something doctors and patients must deal with every day.
Some doctors already believed, before the firings at ACIP, that the CDC was no longer trustworthy under Kennedy's leadership; his unilateral change to the Covid vaccine guidance in May was enough to convince them. In a media call last week, experts from the Infectious Disease Society of America urged patients and providers in the short term to consult with professional medical societies — not the CDC — on vaccine recommendations. They considered those groups, as well as guidance from European health authorities, the best substitutes we currently have for information on vaccines if the CDC's recommendations can no longer be taken at face value.
'It's been a confusing several days, confusing last two weeks, and I'm not sure that confusion is going to be abated in the near future,' John Lynch, an infectious disease doctor at the University of Washington, said on the call.
'These are evidence-based guidelines developed by experts in the field using transparent methods and published publicly,' Lynch said.
Kennedy, in explaining his change to the Covid vaccine guidelines, said he wanted to encourage shared decision-making between providers and their patients. The CDC guidance would be only one consideration in the decision whether to vaccinate, rather than a firm recommendation. The doctors from the IDSA said that such conversations are already to be considered best practice among physicians — and noted Kennedy's undermining of trust in the federal vaccine policy would now make them more important.
'I would just emphasize the need to have a good source of information when this situation occurs. If indeed shared decision making is going to occur, we always do our research,' Dr. Flor Muñoz-Rivas at Baylor College of Medicine said. 'But go to the proper sources.'
What are the long-term risks?
There is a lot we don't know right now: Who will be named to the new panel? Will they change existing vaccine recommendations? Will they approve new ones? But the experts warned that Kennedy's rhetoric alone risks undermining people's confidence in vaccinations.
'All health care decisions are shared decision-making; this is not a special concept that's only rolled out for conversations like vaccination,' Lynch said on the IDSA call. 'As an infectious disease doctor, when I talk to a patient about treatment or diagnostics, it is a conversation. It is shared decision-making.'
Kennedy has quickly disrupted decades of public health consensus.
Anyone who watched the sometimes contentious ACIP meetings during the pandemic saw the members grappling with genuinely vexing questions about who should be prioritized for vaccination in a public health emergency. The pandemic featured rare examples of Biden CDC director Rochelle Walensky overruling the panel in certain cases in which the experts actually recommended against more vaccinations. (Walensky said she overrode the guidance to align the CDC with a separate recommendation from the FDA's advisory committee, and cited the narrow 9-6 vote against the recommendation.) Those scenes should have helped dispel the notion that they were acting as a rubber-stamp for any new shot Big Pharma produced.
But the nation's top health official is now telling Americans that they should never have trusted the ACIP, which risks pushing more people to skip routine immunization. Shortly after the country declared measles eradicated in 2000, 94 percent of adults said childhood immunizations were extremely or very important. But that consensus has since weakened: 69 percent of Americans said the same in 2024. If changing opinion leads to declining vaccination rates, diseases that we successfully stamped out through vaccines to rebound — which is exactly what we are seeing now with measles.
The US is experiencing its highest number of measles cases since the 1990s, nearing 1,200 as of this writing. One outbreak that accounts for most of those cases took off in a small Texas community where vaccination rates had fallen far below the 95-percent threshold that is considered necessary to stop the virus's spread.
Other knock on effects could hurt Americans who still want to get vaccinated. Pharma companies, the target of so much of Kennedy's criticism, could decide to stop pursuing new vaccines if they believe the federal government will limit access as much as possible, shrinking the world's biggest pharmaceutical market. Vaccines are not big moneymakers for drug companies, and they have often relied on the US government's support to develop new ones.
Kennedy, however, has canceled major vaccine development contracts during his first few months as health secretary, including a $700 million contract with Moderna, one of two companies that produced the mRNA Covid vaccines, to work on a universal flu shot.
Kennedy has quickly disrupted decades of public health consensus. For now, the best reaction is, oddly enough, for patients and providers to take him at his word when he says people should not take medical advice from him — and make their own decisions in collaboration with their doctors.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

RFK Jr. picks eight for vaccine panel after firing all 17 members
RFK Jr. picks eight for vaccine panel after firing all 17 members

Fox News

time39 minutes ago

  • Fox News

RFK Jr. picks eight for vaccine panel after firing all 17 members

Health and Human Services Secretary Robert F. Kennedy Jr. announced Wednesday that he has selected eight new people to join the national vaccine panel after firing all 17 of its members. In an X post, Kennedy revealed that he "took a major step towards restoring public trust in vaccines" on Monday by reconstituting the Advisory Committee for Immunization Practices (ACIP). "I retired the 17 current members of the committee. I'm now repopulating ACIP with the eight new members who will attend ACIP's scheduled June 25 meeting," Kennedy wrote on Wednesday. "The slate includes highly credentialed scientists, leading public-health experts, and some of America's most accomplished physicians. All of these individuals are committed to evidence-based medicine, gold-standard science, and common sense." The new members are: Joseph R. Hibbeln, MD; Martin Kulldorff, MD, PhD; Retsef Levi, PhD; Robert W. Malone, MD; Cody Meissner, MD; James Pagano, MD; Vicky Pebsworth, OP, PhD, RN; and Michael A. Ross, MD. The secretary said all eight people "have each committed to demanding definitive safety and efficacy data before making any new vaccine recommendations." He said the committee will review safety and efficacy data for the current schedule." Notably, Kulldorff was one of the co-authors of the Great Barrington Declaration, which was written alongside Dr. Sunetra Gupta of Oxford University and Dr. Jay Bhattacharya of Stanford University. The declaration, published in October 2020, promoted lifting lockdown orders sooner and allowing COVID-19 to spread among young, healthy people to more quickly reach herd immunity. The strategy also included precautions to shield those most vulnerable to severe illness, and the authors said the approach would help mitigate the long-term societal and economic harms of prolonged lockdown orders. It was condemned harshly at the time by the World Health Organization and Dr. Anthony Fauci, then-Director of the U.S. National Institute of Allergy and Infectious Diseases. On Tuesday, before he announced his picks, Kennedy said, "We're going to bring great people onto the ACIP panel – not anti-vaxxers – bringing people on who are credentialed scientists." Kennedy on Monday ousted all 17 members of the ACIP, saying he would appoint a new group before the next scheduled meeting in late June. The agenda for that meeting has not yet been posted, but a recent federal notice said votes are expected on vaccinations against flu, COVID-19, HPV, RSV and meningococcal bacteria. ACIP members typically serve staggered four-year terms, although several appointments were delayed during the Biden administration before positions were filled last year. The voting members all have scientific or clinical expertise in immunization, except for one "consumer representative" who can bring perspective on community and social facets of vaccine programs. The committee, created in 1964, makes recommendations to the director of the Centers for Disease Control and Prevention. Kennedy provided a brief biography of each of his new picks. Hibbeln is a psychiatrist and neuroscientist with a career in clinical research, public health policy and federal service. "As former Acting Chief of the Section on Nutritional Neurosciences at the National Institutes of Health, he led research on immune regulation, neurodevelopment, and mental health," Kennedy wrote. "His work has informed U.S. public health guidelines, particularly in maternal and child health. With more than 120 peer-reviewed publications and extensive experience in federal advisory roles, Dr. Hibbeln brings expertise in immune-related outcomes, psychiatric conditions, and evidence-based public health strategies." Kulldorff is a biostatistician and epidemiologist formerly at Harvard Medical School and a leading expert in vaccine safety and infectious disease surveillance. "He has served on the Food and Drug Administration's Drug Safety and Risk Management Advisory Committee and the CDC's Vaccine Safety Subgroup of the Advisory Committee on Immunization Practices, where he contributed to national vaccine safety monitoring systems," Kennedy wrote, adding that he developed tools used "for detecting disease outbreaks and vaccine adverse events.," and has expertise that "includes statistical methods for public health surveillance, immunization safety, and infectious disease epidemiology." Levi is the Professor of Operations Management at the MIT Sloan School of Management and a leading expert in healthcare analytics, risk management, and vaccine safety. "Dr. Levi has collaborated with public health agencies to evaluate vaccine safety, including co-authoring studies on mRNA COVID-19 vaccines and their association with cardiovascular risks. His research has contributed to discussions on vaccine manufacturing processes, safety surveillance, and public health policy," Kennedy wrote, adding that Levi "has also served on advisory committees and engaged in policy discussions concerning vaccine safety and efficacy," and that his "work continues to inform national and international debates on immunization safety and health system resilience." Malone is a physician-scientist and biochemist known for his early contributions to mRNA vaccine technology, specifically "foundational research in the late 1980s on lipid-mediated mRNA delivery, which laid the groundwork for later developments in mRNA-based therapeutics," Kennedy wrote, adding that Malone's "expertise spans molecular biology, immunology, and vaccine development." Meissner is a Professor of Pediatrics at the Geisel School of Medicine at Dartmouth and a nationally recognized expert in pediatric infectious diseases and vaccine policy. "He has served as Section Chief of Pediatric Infectious Disease at Dartmouth-Hitchcock Medical Center and has held advisory roles with both the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA)," Kennedy wrote, adding that Meissner was a voting member of the CDC's Advisory Committee on Immunization Practices and the FDA's Vaccines and Related Biological Products Advisory Committee, through which "he has contributed to national immunization guidelines and regulatory decisions." "His expertise spans vaccine development, immunization safety, and pediatric infectious disease epidemiology. Dr. Meissner has also been a contributing author to American Academy of Pediatrics policy statements and immunization schedules, helping shape national standards for pediatric care." Pagano is a board-certified Emergency Medicine physician with over 40 years of clinical experience following his residency at UCLA. "He has worked in diverse emergency settings, from Level 1 trauma centers to small community hospitals, caring for patients across all age groups, including infants, pregnant women, and the elderly," Kennedy wrote, adding that he has also served on various committees and medical executive boards. "He is [a] strong advocate for evidence-based medicine." Pebsworth earned a doctorate in public health and nursing from the University of Michigan. "She has worked in the healthcare field for more than 45 years, serving in various capacities, including critical care nurse, healthcare administrator, health policy analyst, and research scientist with a focus on public health policy, bioethics, and vaccine safety," Kennedy wrote, pointing to her current leadership role with the National Association of Catholic Nurses, and previous positions with the FDA's Vaccine and Related Biological Products Advisory Committee, the National Vaccine Advisory Committee's 2009 H1N1 Vaccine Safety Risk Assessment Working Group and Vaccine Safety Working Group. Ross is a Clinical Professor of Obstetrics and Gynecology at George Washington University and Virginia Commonwealth University, with a career spanning clinical medicine, research, and public health policy. "He has served on the CDC's Advisory Committee for the Prevention of Breast and Cervical Cancer, where he contributed to national strategies for cancer prevention and early detection, including those involving HPV immunization," Kennedy wrote, pointing to his experience with "clinical investigations with immunologic relevance," advising organizations like the American College of Obstetricians and Gynecologists, and advocacy efforts related to women's health. "His continued service on biotech and healthcare boards reflects his commitment to advancing innovation in immunology, reproductive medicine, and public health," Kennedy added.

Home Medical Equipment Market is expected to grow at a steady CAGR of 4.5% through 2034
Home Medical Equipment Market is expected to grow at a steady CAGR of 4.5% through 2034

Yahoo

time41 minutes ago

  • Yahoo

Home Medical Equipment Market is expected to grow at a steady CAGR of 4.5% through 2034

Home Medical Equipment MarkeT Outlook, Trends and Forecast to 2034 Luton, Bedfordshire, United Kingdom, June 12, 2025 (GLOBE NEWSWIRE) -- Market Overview The global home medical equipment market is witnessing a transformative shift driven by evolving healthcare delivery models, technological integration, and rising patient preference for at-home care. Valued at approximately USD 45 billion in 2024, the market is projected to grow at a Compound Annual Growth Rate (CAGR) of 4.5%, reaching USD 69 billion by 2034. This steady growth is primarily supported by an aging global population, the increasing prevalence of chronic illnesses, and the subsequent need for cost-effective, home-based health management solutions. Patients and caregivers are increasingly leaning towards home care due to its convenience, affordability, and ability to reduce hospital readmissions. Download PDF Brochure: Key Growth Drivers A significant driver of market expansion is the growing burden of chronic diseases such as diabetes, cardiovascular disorders, and respiratory conditions. These require ongoing management, often best conducted in the comfort of a patient's home. Additionally, the global demographic shift towards an older population has intensified the demand for home-based care, especially for patients with mobility limitations or long-term conditions. The advancement and adoption of telehealth, Internet of Things (IoT)-enabled devices, and wearable healthcare technology further contribute to this growth. These innovations have made it easier for patients to track their health metrics remotely and for healthcare professionals to monitor progress without physical visits. Enhanced connectivity and patient engagement tools are also driving better clinical outcomes, thus fueling adoption. Market Restraints and Challenges Despite promising growth prospects, the home medical equipment market faces notable hurdles. Regulatory variability across regions poses challenges for device approvals and commercialization. The lack of harmonized standards often leads to delays in product launches and increases compliance costs. Moreover, disparate reimbursement policies across countries complicate the adoption of home medical devices, especially in low-to-middle-income economies where public health coverage is limited. Supply chain disruptions, worsened by global events such as the COVID-19 pandemic and geopolitical tensions, have led to raw material shortages and increased production costs. Moreover, pricing pressures and competition from low-cost manufacturers further strain profit margins, making it difficult for companies to balance affordability and innovation. Segmentation Analysis By Product Type The market is segmented into monitoring and therapeutic devices, mobility assist devices, home respiratory equipment, sleep apnea devices, wound care, IV equipment, and other categories. Monitoring and therapeutic devices dominate the segment, accounting for roughly 30% of the market share. These include glucose monitors, blood pressure monitors, and other devices critical for chronic disease management. Their adoption is fueled by technological integration, especially telehealth compatibility. Mobility assist devices, including wheelchairs and walkers, contribute approximately 20% of the total share. Their demand is closely tied to the aging population and innovations such as lightweight materials and ergonomic designs. Home respiratory equipment, which includes oxygen concentrators and nebulizers, holds an 18% share. The spike in respiratory ailments, including long-term effects of COVID-19, has significantly driven growth in this segment. By End User The homecare settings segment leads the market with around 40% of the demand, driven by growing patient preference for personalized care and economic savings compared to institutional care. Hospitals, although traditionally dominant, now account for 25%, often engaging in partnerships with homecare providers to manage post-discharge care. Rehabilitation centers and long-term care facilities represent about 15%, supported by integrated care models that combine therapeutic and mobility support at home. By Distribution Channel Direct sales channels, where companies sell products directly to consumers or care facilities, account for nearly 30% of the market. This approach offers customized solutions and stronger customer relationships. Online sales, contributing to 28%, are growing rapidly due to consumer convenience and the rising popularity of e-commerce. Meanwhile, retail pharmacies and medical equipment stores together represent about 20%, supported by their accessibility and integration with health services. By Demographics The geriatric population makes up 60% of the market, reflecting their higher demand for home medical equipment due to age-related conditions. Adults, particularly those managing chronic conditions at home, contribute 25%, while the pediatric segment comprises 15%, driven by parental preferences for home-based treatment solutions. Browse full Report - Market Segmentation Product Type: Monitoring and Therapeutic Devices Mobility Assist Devices Home Respiratory Equipment Sleep Apnea Devices Wound Care Equipment Home IV Equipment Other Home Healthcare Equipment End-User: Hospitals Homecare Settings Rehabilitation Centers Long-term Care Facilities Assisted Living Facilities Distribution Channel: Direct Sales Online Sales Retail Pharmacies Medical Equipment Stores Demographics: Age Group (Pediatrics, Adults, Geriatrics) Gender (Male, Female) Socioeconomic Status (Low, Medium, High-income groups) Regional Insights North America leads the global market, contributing approximately 40% of total revenue in 2024. The region benefits from robust healthcare infrastructure, favorable reimbursement policies, and a high prevalence of chronic conditions. Technological adoption is also significantly high, with telemedicine and IoT devices becoming standard in many care settings. North America is projected to maintain a healthy CAGR of 5.5% through 2034. Europe holds around 25% of the global share, led by countries such as Germany and France. The region is characterized by a growing elderly population, supportive homecare policies, and well-established healthcare systems. The forecast CAGR for Europe is 4.8%, driven by demand for remote care solutions and wearable devices. Asia-Pacific, accounting for 20% of market share in 2024, is expected to grow at the fastest CAGR of 7.2%. Key contributors include China, India, and Japan, where rising disposable incomes, healthcare awareness, and investments in healthcare infrastructure are accelerating adoption. However, regulatory complexities and regional disparities remain challenges. Latin America and the Middle East are emerging regions, each showing potential with projected CAGRs of 6.4% and 6.1%, respectively. Improvements in healthcare access, economic reforms, and increased awareness of homecare benefits are aiding growth, though infrastructural and regulatory barriers persist. Key Market Trends and Opportunities An increasing focus on preventive healthcare is shaping demand for home diagnostics and early detection devices. This shift is accompanied by growing interest in wearables, AI-enabled analytics, and remote patient monitoring systems, offering a promising frontier for device manufacturers. New business models, including equipment-as-a-service and subscription-based offerings, are gaining popularity. These provide affordability and flexibility to users while ensuring stable revenue streams for providers. Moreover, partnerships between device manufacturers and digital health platforms are becoming a norm, resulting in integrated care solutions that improve patient adherence and satisfaction. Emerging areas of opportunity include mental health support tools and chronic disease management platforms, both of which require consistent monitoring and therapy that can be effectively managed at home. As healthcare transitions toward a patient-centric model, home medical equipment companies have a unique opportunity to redefine care delivery. Buy Now: Recent Market Developments Key Competitors Philips Healthcare Invacare Corporation Medtronic ResMed Baxter International Inc. Johnson & Johnson Fresenius Medical Care AG & Co. KGaA Hill-Rom Holdings, Inc. Drive DeVilbiss Healthcare Arjo AB GE Healthcare Omron Healthcare SunMed Amedisys Inc. althera Health1. Philips Healthcare Month & Year: October 2023 Type of Development: Product Launch Detailed Analysis: In October 2023, Philips Healthcare launched an innovative range of portable home ventilators aimed at improving respiratory care for patients with chronic obstructive pulmonary disease (COPD). This launch is significant as it responds to an increasing global demand for at-home healthcare solutions, especially post-pandemic, where many patients prefer or are required to manage their health from home. The portable nature of these ventilators facilitates easy transport and increased accessibility, appealing to both consumers and healthcare providers seeking to enhance patient care. As healthcare systems globally pivot towards value-based care models, products like Philips' new ventilators may help drive a competitive edge by offering enhanced patient-centric solutions, thereby potentially increasing market shares among key competitors. This strategic move reflects a trend towards integrating advanced technology in home medical equipment, likely setting new standards for functionality and user experience. 2. Invacare Corporation Month & Year: September 2023 Type of Development: Acquisition Detailed Analysis: Invacare Corporation announced its acquisition of a leading telehealth platform in September 2023, marking a pivotal shift towards digital healthcare integration within home medical equipment. This acquisition aligns with emerging trends that emphasize remote patient monitoring and telehealth services, which have surged in demand since the pandemic. The significance of this move lies in Invacare's commitment to providing comprehensive home care solutions that not only offer medical equipment but also integrate vital telehealth technologies. By enhancing their product offerings to include remote monitoring capabilities, Invacare positions itself to capture a growing segment of the market that values digital health tools. Moreover, this acquisition may prompt competitive shifts, as it encourages other players to innovate and expand their offerings in line with technological advancements, further transforming the home healthcare sector. 3. Medtronic Month & Year: August 2023 Type of Development: Regulatory Approval Detailed Analysis: In August 2023, Medtronic obtained regulatory approval for its latest remote monitoring system, designed for chronic disease management in home settings. This system enables healthcare providers to monitor patient health metrics in real-time, facilitating proactive care interventions. The significance of this approval cannot be overstated, considering the increasing emphasis on reducing hospital readmissions and improving care efficiency. Medtronic's system stands to reshape care pathways by allowing timely decision-making based on comprehensive patient data. With the home healthcare market projected to grow substantially, this advancement could drive competitive advantage, compelling other companies to pursue similar regulatory pathways to enhance their offerings. As the technology gains traction, it may also highlight a shift toward integrated care solutions that leverage data analytics and remote technologies, indicating an evolution in home care's operational model. 4. ResMed Month & Year: July 2023 Type of Development: Partnership Detailed Analysis: July 2023 saw ResMed enter into a strategic partnership with a leading digital health company to enhance sleep apnea treatment through data-driven solutions. The partnership aims to integrate wearable technology to monitor sleep patterns effectively and personalize therapy for patients using ResMed devices. This collaboration is significant as it reflects a growing trend towards integrating artificial intelligence and machine learning into patient care. By leveraging technology, ResMed not only improves treatment efficacy but also elevates patient engagement, making adherence to treatment protocols more intuitive. The collaboration could lead to increased market share and customer loyalty for ResMed, setting a precedent for other players to engage in similar innovative partnerships. Those companies that fail to adopt such integrative approaches may find themselves at a competitive disadvantage as the market increasingly values connected healthcare solutions. 5. Baxter International Inc. Month & Year: June 2023 Type of Development: Expansion Detailed Analysis: In June 2023, Baxter International Inc. announced its expansion into the Asian market with the opening of a new manufacturing facility dedicated to home intravenous therapy products. This move reflects Baxter's strategic focus on growing international revenues amidst increasing local demand for home care solutions. By tapping into the burgeoning Asian economy, which is witnessing a rapid shift towards home healthcare due to its cost-effectiveness and patient preference, Baxter is poised to significantly bolster its market presence. This expansion also signifies a competitive shift, as it may encourage other global players to target emerging markets aggressively. The trend towards localized production not only facilitates faster response times to market demands but also positions companies like Baxter to capitalize on regional healthcare initiatives aimed at reducing hospital overcrowding, thereby influencing the overall landscape of home healthcare products. This report is also available in the following languages : Japanese (在宅医療機器市場), Korean (가정용 의료 장비 시장), Chinese (家庭医疗设备市场), French (Marché des équipements médicaux à domicile), German (Markt für medizinische Geräte für den Heimgebrauch), and Italian (Mercato delle apparecchiature mediche domestiche), etc. Request Sample Pages: More Research Finding – Medical Assistive Technology Market The global medical assistive technology market is valued at approximately $45 billion in 2024, with a projected growth to around $81 billion by 2034. This represents a robust Compound Annual Growth Rate (CAGR) of 6.2% from 2025 to 2034. Orthopedic Rehabilitation Aids Market The global orthopedic rehabilitation aids market is poised to reach an estimated value of approximately $10 billion in 2024, driven by an aging population and increasing incidence of musculoskeletal disorders. During the forecast period from 2025 to 2034, the market is projected to expand at a Compound Annual Growth Rate (CAGR) of 6.8%, potentially reaching around $20 billion by 2034. Rehabilitation Medical Device Market The global rehabilitation medical device market is valued at approximately $19.2 billion in 2024, with projections indicating significant growth to reach around $31.5 billion by 2034. This reflects a robust Compound Annual Growth Rate (CAGR) of around 5.1% during the forecast period from 2025 to 2034. Medical Rehabilitation Equipment Market The global medical rehabilitation equipment market is valued at approximately $14 billion in 2024, with expectations to reach around $25 billion by 2034, indicating a robust growth trajectory. This represents a Compound Annual Growth Rate (CAGR) of about 6.4% from 2025 to 2034. Amyotrophic Lateral Sclerosis Device Market The global market for amyotrophic lateral sclerosis (ALS) devices is valued at approximately $2.1 billion in 2024. This market is anticipated to reach around $3.6 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of 5.3% during the forecast period from 2025 to 2034. Aid for The Elderly and Disabled Market The global market for aid for the elderly and disabled is projected to reach approximately $95 billion in 2024, with expectations to expand significantly over the next decade. By 2034, the market value is forecasted to soar to around $150 billion, reflecting a robust Compound Annual Growth Rate (CAGR) of approximately 4.7% during the period from 2025 to 2034. Assistive Devices For The Elderly and Disabled Market The global market for assistive devices for the elderly and disabled is valued at approximately $35 billion, with a robust projected growth trajectory. By 2034, this market is anticipated to reach $70 billion, reflecting a Compound Annual Growth Rate (CAGR) of about 7.3%. Stroke Assistive Devices Market The stroke assistive devices market is valued at approximately $2.5 billion in 2024, driven by the increasing prevalence of strokes and a growing geriatric population. This segment is expected to reach around $4.5 billion by 2034, reflecting a robust investment in healthcare infrastructure and advanced rehabilitation solutions. The projected Compound Annual Growth Rate (CAGR) during the forecast period from 2025 to 2034 is estimated at 6.1%. U.S. Physical Therapy Equipment Market The U.S. physical therapy equipment market is valued at approximately $3.2 billion in 2024, with expectations to reach around $5.2 billion by 2034, reflecting a Compound Annual Growth Rate (CAGR) of about 5.0% during the forecast period from 2025 to 2034. Pulsed Light Medical Equipment Market The global pulsed light medical equipment market is poised for significant growth, with a current valuation of approximately $540 million in 2024. Projecting forward, this market is expected to reach around $1.2 billion by 2034, reflecting robust demand driven by advancements in medical technology and increasing adoption of non-invasive treatment options. The market is anticipated to grow at a Compound Annual Growth Rate (CAGR) of about 8% during the forecast period from 2025 to 2034. Xenon Flash Lamp Market The global xenon flash lamp market is valued at approximately $450 million in 2024, with projections indicating a robust growth trajectory, reaching approximately $675 million by 2034. This represents a compound annual growth rate (CAGR) of around 4.5% over the forecast period from 2025 to 2034. Polarizing Beam Splitters PBS Market The global market for polarizing beam splitters (PBS) is valued at approximately $1.2 billion in 2024, with an anticipated expansion to $2.5 billion by 2034. This growth trajectory suggests a robust Compound Annual Growth Rate (CAGR) of around 8.1% during the forecast period from 2025 to 2034. Special Equipment Manufacturing Market The global special equipment manufacturing market is projected to reach approximately USD 250 billion in 2024. This sector encompasses a diverse array of industries, including construction, mining, and specialized machinery. The market is expected to exhibit robust growth, reaching an estimated value of USD 425 billion by 2034, reflecting a Compound Annual Growth Rate (CAGR) of 5.3% from 2025 to 2034. Plasma Cleaners Market The global plasma cleaners market is valued at approximately $450 million, with projections estimating a market value of around $1.1 billion by 2034. This growth trajectory reflects a Compound Annual Growth Rate (CAGR) of about 9% over the forecast period from 2025 to 2034. Strain Wave Gearing Devices Market The global strain wave gearing devices market is estimated to reach a valuation of approximately USD 550 million in 2024, with a robust projected growth trajectory anticipating a market value of around USD 1.1 billion by 2034. This reflects a notable Compound Annual Growth Rate (CAGR) of approximately 7.2% over the forecast period from 2025 to 2034. Galvanometer Scanners Market The global galvanometer scanners market is expected to reach a value of approximately $250 million in 2024, driven by rising demand across industries such as medical, defense, and manufacturing for precise laser applications and automation. Projections for the market suggest a robust growth trajectory, with a forecasted value of about $450 million by 2034. Pet Medical Equipment Market The global pet medical equipment market is poised for significant growth, with an estimated market value of approximately $1.5 billion in 2024. Forecasts indicate a robust expansion, anticipating the market will reach around $2.9 billion by 2034, driven by increasing pet ownership and rising expenditure on pet healthcare. 5-axis CNC Machine Tool Market The global 5-axis CNC machine tool market is valued at approximately $3.5 billion in 2024, with forecasts indicating significant growth, projecting a market value of around $5.8 billion by 2034. This trajectory suggests a robust Compound Annual Growth Rate (CAGR) of about 5.3% during the forecast period from 2025 to 2034. Coaxial Isolators Market The global coaxial isolators market is valued at approximately $1.2 billion in 2024, with projections indicating it will reach around $1.9 billion by 2034. This growth signals a robust Compound Annual Growth Rate (CAGR) of 4.8% during the forecast period from 2025 to 2034. CONTACT: Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Kentucky families must renew Medicaid for first time since pandemic. Here's what to know
Kentucky families must renew Medicaid for first time since pandemic. Here's what to know

Yahoo

time41 minutes ago

  • Yahoo

Kentucky families must renew Medicaid for first time since pandemic. Here's what to know

Starting in July, thousands of families across Kentucky must again renew their Medicaid enrollment— a process one local health provider warns could leave some without necessary insurance coverage. During the COVID-19 pandemic, Kentucky halted annual Medicaid renewals, allowing participants to automatically be reenrolled. In 2023, the state ended that policy, requiring Medicaid recipients to go back to submitting enrollment paperwork every year — except for those in the Kentucky Children's Health Insurance Program (KCHIP). KCHIP is a free health insurance program for families with an income at or under 218% of the federal poverty level — or up to $70,000 per year for a family of four. Children under 19, pregnant mothers and mothers within one year of postpartum are eligible to receive KCHIP coverage. When recertification resumed in 2023, the state introduced several flexibilities to ensure vulnerable populations could remain covered, including extending automatic renewal for KCHIP participants. The goal was 'simplify the renewal process, reduce inappropriate terminations and allow the state to manage the increased workload,' according to a document from the Kentucky Department of Medicaid Services. Now, that flexibility is ending, meaning thousands of Kentucky families will start receiving notices to update and recertify their Medicaid eligibility. Here's what to know. Families will get a letter when it's time to recertify and should watch for notices by mail, phone and email. There are also several ways to check Medicaid eligibility and recertify if needed. Visit Call 855.4kynect (855.459.6328) to speak with a caseworker. Visit your local Department for Community Based Services office. Contact a state kynector for assistance through Once enrolled, coverage lasts for 12 months. Even if changes make families ineligible for the program, children retain coverage for the year. Families can miss notifications to reenroll for a lot of reasons, said Bart Irwin, CEO of Family Health Centers, a nonprofit primary care provider with locations across Louisville. Maybe they've changed addresses, incorrectly filled out paperwork or missed deadlines — but that doesn't mean they are not financially eligible for Medicaid or KCHIP. "There's a connection that if parents or caregivers lose Medicaid, it's highly likely a child will lose Medicaid too," Irwin said. "I don't quite understand the connection, but one [reason] I would think is that if the parents miss the opportunity or don't respond correctly to the state's inquiry on their own behalf, it's likely they're not going to on their child's behalf, too." If someone does not respond to a renewal by the deadline, they will be unenrolled from coverage. KCHIP participants and families can call 855-459-6328 as soon as they learn they are unenrolled for lack of response. If they are determined eligible within 90 days of termination, coverage may be rolled back to the day of termination. Irwin said recertification for the KCHIP program could artificially deflate Medicaid rolls, similar to when the state stopped automatic enrollment for adults on Medicaid in 2023. Between April, when recertification restarted, and December 2023, Jefferson County saw more than 28,500 drop off the program's rolls, according to data from the Cabinet of Health and Family Services. Children make up a substantial portion of Medicaid recipients in Jefferson County, with over 108,000 kids receiving coverage. A third of Family Health Centers' Medicaid patients are children under 19. "It would be the same process as going through our kynectors and helping them redo certification, we know they're eligible, right?" Irwin said. "It's going to be the bureaucratic process that's going to harm the kids. It's missing the letter, or not putting the right information in, or forgetting some information, that's what's going to knock kids off." Reach reporter Keely Doll at kdoll@ This article originally appeared on Louisville Courier Journal: Kentucky families must again renew Medicaid. Here's how to recertify

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store